Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 1 September 2017, 10:06 HKT/SGT

Source: Eisai
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session

TOKYO, Sept 1, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima/Kisplyx (lenvatinib mesylate, "lenvatinib", selective inhibitor of receptor tyrosine kinases with a novel binding mode), Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics inhibitor), and E7046 (prostaglandin E2 receptor EP4 inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2017 Congress , taking place in Madrid, Spain, from September 8 to 12, 2017.

At the ESMO 2017 Congress, there will be an oral presentation on the results of a health-related Quality of Life analysis of patients from a Phase III clinical trial (REFLECT/Study 304) of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma, and a separate oral presentation on the results of an analysis of biomarkers from the same study. In addition, there will be an oral presentation on the results of the metastatic renal cell carcinoma cohort from a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with anti-PD-1 antibody pembrolizumab.

There are six poster presentations scheduled, including presentations on the results of a primary analysis of a Phase II clinical trial of lenvatinib in biliary tract cancer, and the results of a Phase I clinical trial of E7046.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.

Sept 1, 2017 10:06 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Feb 27, 2018 09:33 HKT/SGT
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Feb 21, 2018 08:25 HKT/SGT
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Feb 16, 2018 07:34 HKT/SGT
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Feb 12, 2018 09:03 HKT/SGT
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Feb 1, 2018 16:20 HKT/SGT
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Jan 22, 2018 09:51 HKT/SGT
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Jan 20, 2018 18:32 HKT/SGT
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: